Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
induced pluripotent stem cell-derived platelets
- Development stage
- Unknown
- Lead developer
- Megakaryon
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Induced pluripotent stem cell-derived platelets (iPSC-PLTs) are an autologous cell therapy developed for the treatment of thrombocytopenia, specifically in patients with aplastic anemia and alloimmune platelet transfusion refractoriness (allo-PTR). The production process involves reprogramming a patient's peripheral blood mononuclear cells into iPSCs, which are then differentiated into immortalized megakaryocyte progenitor cell lines (imMKCLs) through the overexpression of c-MYC, BMI1, and BCL-XL. These imMKCLs are expanded and then induced to undergo thrombopoiesis in turbulent flow bioreactors to generate functional platelets. This approach aims to provide a stable supply of HLA-matched platelets for patients who have developed antibodies against donor platelets. The therapy was evaluated in the first-in-human iPLAT1 clinical trial conducted at Kyoto University Hospital.
- Other names
- iPS cell-derived plateletsautologous iPSC-derived plateletsimMKCL-derived platelets
Beyond the preview
Go deeper on induced pluripotent stem cell-derived platelets.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on induced pluripotent stem cell-derived platelets.